Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 12/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 12/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2956447 | 0.83 | ACE (0.41) | MIFGABRA1 | |
| SCHEMBL2961448 | 0.83 | ACE (0.41) | MIFGABRA1 | |
| SCHEMBL2964054 | 0.78 | MIF (0.51) | MIFGABRA1SMN1; SMN2 | |
| SCHEMBL2949821 | 0.77 | MIF (0.46) | MIFGABRA1SMN1; SMN2 | |
| SCHEMBL2958775 | 0.76 | KDM4E (0.47) | MIFGABRA1SMN1; SMN2 | |
| SCHEMBL2959069 | 0.76 | MIF (0.56) | CYP1A2CYP2C19MIFGABRA1SMN1; SMN2 | |
| SCHEMBL13199817 | 0.74 | CXCR4 (0.52) | MIFGABRA1SMN1; SMN2 | |
| SCHEMBL2961677 | 0.74 | MIF (0.59) | CYP1A2CYP2C19MIFGABRA1SMN1; SMN2 | |
| SCHEMBL2959722 | 0.74 | MIF (0.53) | CYP1A2CYP2C19MIFGABRA1SMN1; SMN2 | |
| SCHEMBL2956546 | 0.74 | MIF (0.53) | CYP1A2CYP2C19MIFGABRA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | CYP1A2 2284/4885PDCD1 558/4885CD274 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.